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1. Introduction 
Solid organ or stem cell transplantation is a well established procedure in the treatment of end-
stage diseases (renal disease, chronic liver failure, end-stage pulmonary disease, heart failure). 
Improved outcome for these patients has allowed us to study some of the complications. One 
of these is metabolic bone disease, which can hinder their long-term survival and quality of 
life. In this chapter we have review our current understanding of the pathophysiology of bone 
loss before and after solid organ transplantation, and review recommendations for the 
prevention and treatment of osteoporosis in patients accepted into organ transplantation 
programs. There are a  number of risk factors contributing to bone loss in these patients: 
hypogonadism, vitamin D deficiency, malabsorption, low body weight, physical inactivity, 
excessive use of tobacco or alcohol and immunosuppressive therapy. Management of 
pretransplant risk factors has improved, resulting in better bone mineral density (BMD) levels 
before transplantation (Guichelaar et al., 2006). After transplantation, rapid and marked bone 
loss is observed in the first 3-6 months. The speed of the bone loss suggests that corticosteroids 
are heavily involved. Greater bone loss at vertebral and hip sites and high rates of incident 
fragility fractures have been reported (Leidig-Bruckner et al., 2001).  
2. Pathogenetic factors 
Many factors contribute to the pathogenesis of osteoporosis after organ transplantation. 
These include bone disease preceding transplantation, immunosuppressive medications, 
nutritional and lifestyle factors, and derangements of the parathyroid-calcium-vitamin D 
and the pituitary gonadal axes (Table 1). However, specific pathophysiological features can 
also be found in different forms of end-stage diseases. 
2.1 Pre-existing bone disease 
2.1.1 Kidney disease  
End-stage renal disease (ESRD) is associated with a form of bone disease that is generically 
referred as “renal osteodystrophy”. Many mechanisms are involved in its pathophysiology 
including calcitriol deficiency, hypocalcemia, hyperphosphatemia, secondary 
hyperparathyroidism, metabolic acidosis, and aluminum overload. Kidney transplantation 
will improve many aspects of renal osteodystrophy, but parathyroid hyperplasia may not 
regress even when normal kidney function returns.  
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General Risk factors 
Vitamin D Deficiency and secondary Hyperparathyroidism 
Hypogonadism 
Inactivity / Immobilization 
Poor Nutrition 
Low body weight 
End Stage Renal Disease 
Secondary hyperparathyroidism  
Adinamic bone disease 
Osteomalacia 
Mixed Uremic disease 
Metabolic Acidosis 
Long term hemodyalysis 
Medications: loop diuretics, heparin and warfarin. 
Diabetic nephropathy 
-microglobulin amyloidosis 
End-Stage Lung disease 
Smoking 
Chronic use of glucocorticoids 
Hypercapnia 
Hypoxia 
Pancreatic insufficiency (cystic fibrosis). 
Failure to attain peak bone mass (in patients who have cystic fibrosis). 
Heart failure 
Mild renal insufficiency 
Medication: loop diuretics, heparin and warfarin. 
Failure to attain peak bone mass (in patients with congenital heart disease). 
End-Stage Liver Disease 
Alcohol abuse 
Cholestatic liver disease 
Bone marrow transplant recipients 
Chronic use of glucocorticoids 
Chemotherapy 
Growth hormone deficiency (in children) 
Table 1. Risk Factors contributing to bone fragility before transplantation 
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There are several histological subtypes of renal osteodystrophy. The most common is 
osteitis fibrosa, characterized by increased bone turnover and typically associated with high 
serum PTH levels (secondary hyperparathyroidism). Osteomalacia is the least common 
type, with low bone formation and accumulation of unmineralized osteoid. A mixed disease 
of both, combining increased resorption and increased osteoid, can also exist. Adynamic 
bone disease is characterized by low bone formation without evidence of fibrosis. 
Compared to the general population ESRD patients are 4.4 fold more likely to have a hip 
fracture and the prevalence of vertebral fracture is 21% higher (Alem et al., 2000). Some of 
the risk factors for fractures in general population are also seen in patients with renal 
osteodystrophy: older age, female gender, or low body weight. Specific risk factors in end-
stage renal patients are duration of dialysis and peripheral vascular disease (Sethman-Breen 
et al., 2000).Although BMD in patients with renal osteodystrophy tends to be lower in 
cortical sites (forearm and hip) than cancellous sites (spine), there is not a clear relationship 
between the different histological types of renal osteodystrophy and bone density (Gerakis 
et al., 2000). Furthermore, BMD does not consistently predict fractures after kidney 
transplantation (Grotz et al., 1994). It is important to note that measurement of bone mineral 
density (BMD) and WHO criteria cannot be used to diagnose osteoporosis in patients with 
ESRD. This is because any of the several possible histological forms of renal bone disease 
may all be associated with low, normal or even elevated BMD. 
2.1.2 Lung disease 
Patients who are candidates for lung transplantation are highly likely to have osteoporosis 
before surgery. A retrospective study in patients with diffuse parenchymal lung disease 
referred for lung transplantation revealed that 30% and 49% of patients had lumbar or 
femoral osteoporosis respectively (Shane et al., 1996). Other authors found osteoporosis in 
50% of the patients at lumbar spine and 61% at femoral neck (Tschopp et al., 2002). Several 
risk factors such as hypoxemia, malnutrition, vitamin D deficiency, smoking, decreased 
immobility and low body weight are involved. Cystic fibrosis is associated with additional 
risk factors such as hypogonadism, inflammatory bone-resorbing cytokines and pancreatic 
insufficiency that may impair the absorption of calcium and Vitamin D. In addition, most of 
the patients who undergo lung transplantation have experienced prior glucocorticoid 
therapy (Tschopp et al., 2002).  
2.1.3 Cardiac disease 
Osteoporosis and osteopenia are common in patients with severe congestive heart failure 
(CHF). Lumbar spine osteopenia has been found in 43% of patients, and spine osteoporosis 
(T-score ≤ -2.5 or Z-score ≤-2.0) in 12-40% of patients. Biochemical markers of bone turnover 
suggest the presence of increased bone resorption. Involved factors that contribute to bone 
loss include low serum 25-OH vitamin D, hypogonadism, immobilization and loop diuretic 
use. Long-term therapy with heparin has been associated with bone loss and vertebral 
fractures. However, in CHF oral anticoagulants (warfarin) usually are used chronically 
instead of heparin. Warfarin blocks vitamin K-dependent gamma-carboxylation of 
osteocalcin and impairs its binding with calcium. Secondary hyperparathyroidism may 
occur due to impaired renal function and abnormal vitamin D metabolism. 
Hypogonadotropic hypogonadism appears to be very common in males with CHF. Up to 
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30% of males with CHF evaluated before transplantation have low levels of testosterone, 
and this proportion could further increase after cardiac transplantation (Cohen et al., 2003). 
We have found that trabecular bone loss was related to pretransplantation time of waiting. 
Also bone resorption markers were increased at  this  stage reflecting a high bone turnover 
(Garcia Delgado et al., 2000). 
2.1.4 Liver disease 
Osteoporosis and osteopenia are frequent complications of chronic liver disease. Its 
prevalence is high in patients waiting for liver transplant, especially in cholestatic liver 
disease. In the most important series, densitometric osteoporosis has been described 
between 31% to 44% (Lopez et al., 1993, Newton et al., 2001, Solerio et al., 2003;Ninkovic et 
al.,  2001; Guichelaar et al..,  2006). 
A low bone turnover state has been found in biochemical measurements and 
histomorphometric analysis (Diamond et al., 1989). Osteocalcin levels are low and correlate 
with bone formation rate on bone biopsies, and show increases after successful 
transplantation. However, some reports describe increases in parameters reflecting bone 
resorption (osteoclast number and bone resorption surface) (Cuthbert  et al., 1984). 
Reduced bone formation has been related to several toxic factors that could inhibit 
osteoblast function as excessive alcohol intake or hyperbilirrubinemia. Also a lower IGF-1 
sinthesis, that has a direct trophic action upon the osteoblast could be involved. 
Glucocorticoid used simultaneously reduces bone formation and increases bone resorption. 
Vitamin D metabolism plays a pivotal role. Patients with end-stage liver disease frequently 
have low serum levels of 25(OH) vitamin D, since 25-hydroxylation of colecalciferol occurs 
at the hepatocyte. Fat malabsorption also decreases 25 (OH) vitamin D. In addition, 
increased vitamin D catabolism, reduced levels of vitamin D-binding protein (DBP), or 
reduced sunlight exposure can further decrease vitamin D serum levels. However, true 
osteomalacia is rare in cirrhotic patients (Table 2). Typically, successful liver transplantation 
reverses most of these factors. Hypogonadism frequently associated in these patients, could 
be partially responsible for the increased bone resorption. 
 
 
Reducing bone formation: 
-Ethanol excess 
-Iron overload (hemochromatosis) 
-Hyperbilirrubinemia 
-Glucocorticoid use 
-Decreased IGF-1 
-Decreased 25 (OH) vitamin D3 
Increasing bone formation: 
-Hypogonadism 
-Glucocorticoid use 
 
 
Table 2. Involved factors in hepatic osteodystrophy. 
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In the past two decades significant changes have occurred in the management of chronic 
liver disease, the waiting time for transplantation and immunosuppressive therapy. 
Recently an improvement in lumbar spine BMD T-scores pretransplant from -2.5 before 1990 
to -1.7 after 1996 has been described (Guichelaar et al., 2006). This data can help to clarify the 
etiology of bone loss: the severity of liver disease has not changed, the duration of disease 
before transplantation has been extended and patients can reach older ages. However, 
nutritional status has improved and bilirubin values decreased. These factors may have 
contributed to increase BMD before transplantation.  
2.1.5 Bone marrow  
Bone marrow transplant (BMT) recipients have many known risk factors for developing 
bone loss: Failure to attain peak bone mass in children and adolescents, hypogonadism, 
inactivity and induction and consolidation regimens with high dose of chemotherapy, 
glucocorticoids and irradiation that may damage bone marrow stromal cells and colony-
forming unit fibroblast , reducing osteoblastic differentiation. A study in patients before 
BMT (after chemotherapy) show osteopenia in 24% and osteoporosis in only 4% (Schulte et 
al., 2000).  
2.2 Related to transplantation: Immunossupressor drugs and other factors 
2.2.1 Glucocorticoids 
Early bone loss has been observed in all solid organ transplants in the first 3 to 6 months, 
increasing the incidence of osteoporosis and osteopenia (Rodino et al., 1998; Leidig-Bruckner 
et al., 2001; Eastell et al., 1991). Bone loss primarily affects the spine and proximal femur. 
Some authors found greater impairment at this level (Keogh et al., 1999; Ninkovic et al., 
2002). In patients who already have osteopenia or osteoporosis, this subsequent bone loss 
can result in a higher number of fractures (Eastell et al.., 1991; Leidig-Bruckner et al., 2001). 
Traditionally, it has been assumed that high doses of glucocorticoids required for 
immunosuppression play a major role in this loss. High doses (≥ 1 mg/kg/day) are 
commonly prescribed immediately after transplantation, with gradual dose reduction over 
several weeks or months. Total GCs exposure depends on the transplanted organ, number 
of rejection episodes, and different immunosupressive regimens. 
The natural history of post-transplantation osteoporosis suggests that there are two main 
phases: the early one and the late one. The factors affecting the skeleton differ between this 
two phases. 
The mechanisms associated with bone loss due to glucocorticoid treatment in the first phase 
are (Table 3): 
1) An increase in bone resorption as a result of increased urinary calcium, decrease in 
intestinal calcium absorption, secondary hyperparathyroidism and hypogonadotropic 
hypogonadism; 2) Activation of osteoclastogenesis caused by increase of RANKL and 
decrease of osteoprotegerin (OPG). 3) Corticosteroid treatment decrease the proliferation 
and function of osteoblasts (by inhibiting the gene expression of osteocalcin, collagen type 1 
and IGF-I) and induces its apoptosis (Canalis et al., 2002). (Fig 1) 
In addition to their direct effects on bone tissue, glucocorticoids can induce severe 
myopathy, impairing balance and mobility, decreasing weight-bearing activity and 
increasing fall risk and fractures.  
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Increase in bone resorption as a result of increased urinary calcium. 
Decrease in intestinal calcium absorption. 
Secondary hyperparathyroidism. 
Hypogonadotropic hypogonadism. 
Activation of osteoclastogenesis caused by increase of RANKL and decrease of 
osteoprotegerine (OPG) levels. 
Decrease in proliferation and function of osteoblasts (by inhibiting the gene expression of 
osteocalcin, collagen type 1 and IGF-I). 
Decrease anabolic effects of TGF-beta. 
Induces Osteoblast apoptosis. 
Table 3. Effects of high doses of glucocorticoids in bone loss. 
 
 
 
Fig. 1. Effect of high doses of glucocorticoids in bone loss 
Effect of glucocorticoids in the WNT pathway: The Wnt pathway and the Bone 
Morphogenetic Protein (BMP) seem to be involved in the pathogenesis of glucocorticoid-
induced osteoporosis, suppressing osteoblast differentiation and activity. BMP and Wnt 
pathway are regulated by several mechanisms: one of them are proteins that act as 
extracellular antagonists of BMP (Noggin, Chordin, Twisted gastrulation, Grelin, Sclerostin, 
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Follistatin and Dan), while others act as Wnt antagonist: Frizzled-related protein (sFRP), 
Dickkopf (Dkk) and Cerberus. Glucocorticoids can affect these signaling pathways, but the 
exact mechanisms are not been clarified. Recent studies suggest that glucocorticoids induce 
an alteration in osteoblast function by increasing Wnt antagonists with the subsequent 
suppression of this pathway. Recent reseach has shown that dexametasone, increases 
follistatin and DAN (BMP antagonists), sFRP-1(Wnt antagonist) and axin-2 (inhibitor of Wnt 
signal) . Simultaneously, alendronate and PTH (1-34), which have demostrated to be 
effective in the treatment of steroid osteoporosis, were able to antagonize the increase in this 
proteins induced by dexametasone (Hayashi et al., 2008). 
The potential impact of glucocorticoid dose as a determinant of bone loss is supported by 
the absence of bone loss at the lumbar spine and proximal femur in renal transplant patients 
treated with low doses of steroids and tacrolimus (Goffin et al., 2001). We have previously 
reported that steroid withdrawal in patients who have undergone a successful liver 
transplant accelerates the recovery of lumbar spine bone density without adverse effects on 
graft tolerance (Martínez Díaz-Guerra et al., 2002). 
Moreover, higher rates of fracture occurring after cardiac (Shane et al., 1996) and lung 
(Shane et al., 1999) transplantation, in which higher doses of steroids are use, would be 
consistent with their role in the pathogenesis of post transplant osteoporosis.  
The late phase observed in the postrasplant period takes place when the glucocorticoid 
doses are usually tapered below 5 mg per day. Then, osteoblast function recovers and 
consequently, an increase in bone formation and recoupling of bone remodeling activity is 
observed. During this later phase, rates of bone loss slow and there may even be some 
recovery, particularly in cancellous bone (Kulak et al.,  2006). It is also found that despite an 
initial decrease in post transplant BMD, biopsies in the iliac crest showed improvement in 
histomorphometric parameters 4 months later (Guichelaar et al., 2003). 
In conclusion, current evidence suggests that bone loss after transplantation is caused by an 
initial increase in bone turnover and resorption, plus a decrease in bone formation. Later, 
increases in bone formation could overcome resorption. These changes would be consistent 
with the rapid decrease in BMD observed in the first months after transplantation and 
recovery to baseline values, as most of studies show. 
2.2.2 Other immunosuppressive drugs 
The effect of these drugs in humans is difficult to study because they are used in conditions 
that by themselves affect bone remodeling, and they are rarely used in monotherapy so, the 
potential deleterious effect of one single agent could not be ascertained.  
The role of calcineurin inhibitors in post-transplant bone loss is unknown. Tacrolimus is a 
calcineurin inhibitor that suppresses T cell activation and the production and release of IL-2 
and other cytokines. It induces severe trabecular bone loss in rats, but this effect appears to 
be less severe in humans (Epstein, 1996). Cyclosporin A (CyA), another calcineurin inhibitor, 
also appears to have adverse effects in mouse models, inducing high turnover and reducing 
bone mass. Some studies in humans suggest a similar effect in patients with liver (Giannini 
et al., 2000), and cardiac (Thiebaud et al., 1996) transplantation. In a research of 360 patients 
with liver transplantation due to chronic cholestatic liver disease, the post transplant bone 
gain was lower, and the number of fractures was higher in patients treated with CyA than in 
those receiving tacrolimus (Guichelaar et al.,  2007). Other authors have found greater 
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fracture incidence in patiens receiving CyA treatment than in those treated with tacrolimus 
(Monegal et al., 2001). 
In other liver transplanted recipients study, although bone mass losses were similar in 
patients on CyA regimen than in those on tacrolimus, histomorphometric changes after 
transplantation were different between groups. Patients treated with tacrolimus had an 
improvement in trabecular bone architecture compared with patients receiving CyA 
(Guichelaar et al., 2004). These findings suggest that patients treated with tacrolimus may 
have  faster recovery of bone metabolism after the initial phase of bone loss compared with 
those treated with CyA. 
A study comparing CsA monotherapy versus prednisone and azathioprine regimen in renal 
transplant recipients did not found any differences in bone loss or bone histomorphometric 
parameters (Cueto-Manzano et al., 2003). Furthermore, a major side-effect of CsA therapy is 
dose-related nephrotoxicity, often leading to secondary hyperparathyroidism, which may 
also adversely affect bone health. 
Other immunosupresive agents such as Mycophenolate mofetil (104), rapamycin or 
azathioprine have shown no effects on bone in murine models (Maalouf et al., 2005). 
3. Bone loss and fractures after transplantation 
The majority of longitudinal studies show a decrease in bone mineral density at the lumbar 
spine and hip that occurs in the first year after solid organ transplantation. The amount of 
bone loss ranges between 3% and 10%, particularly in the first 3-6 months. Rapid bone loss 
and major involvement of lumbar spine (trabecular bone tissue) are findings probably 
related to the large doses of glucocorticoids used immediately after transplantation. Rates of 
lumbar spine bone loss slow thereafter, with stabilization by 6–12 months and even some 
recovery after liver, lung, and heart transplantation. However, most studies do not 
document recovery of bone mass at the hip. BMD changes after renal transplantation are 
different since continued bone loss after the rapid initial bone loss may be observed. 
Prevalence of densitometric osteoporosis is quite variable depending on type of organ 
transplantation and time elapsed since transplantation (Hawkins et al., 1994).  
With regard to fractures, a high incidence of them (between 20% and 40% in most studies) 
has been documented. In heart and liver transplant recipients, the incidence of new fractures 
parallels the timing of the most rapid bone loss, with most fractures occurring within the 
first year after transplantation (Eastell R, 1991; Henderson et al., 1995; Shane et al., 1996; 
Ramsey-Goldman et al., 1999). 
Fractures usually affect the spine and ribs in liver, cardiac, or lung recipients, whereas long 
bones are more easily fractured in renal transplant recipients. However, fracture incidence 
may have decreased in the last years. This is probably related to the wide implementation of 
immunosuppressive regimens that use lower doses of glucocorticoids and for a shorter 
period of time. Indeed, bone loss and fractures remain unacceptably high in several recent 
studies.  
Risk factors for fractures after transplantation include older age, prevalent fractures before 
transplantation, postmenopausal status, and lower body mass index. Additional risk factors 
in renal transplant recipients include the presence of diabetes mellitus and prolonged 
dialysis. The predictive roles of pretransplantation BMD and cumulative glucocorticoid 
dose are controversial. Associations between these risk factors and bone loss or fractures are 
www.intechopen.com
 
Post-Transplantation Bone Disease 
 
307 
not consistent across studies. Even patients with normal pre-transplant BMD may suffer 
fracture after transplantation. Therefore, it is usually not possible with current clinical tools 
to predict whether individual transplant recipients will fracture after transplantation. 
In a nested case-control study of transplant recipients (kidney, liver, lung, heart), 
multivariate analysis showed that post-transplant fracture rate was highest among those 
with a history of hyperthyroidism, pretransplant diabetes, fracture, or corticosteroid use, 
and among those currently exposed to antidepressants, narcotics, sirolimus, and loop 
diuretics (Shane et al., 2009 uptodate). Use of bisphosphonates or calcitonin was also a 
predictor of fracture, likely indicating the presence of pre-transplant osteoporosis. 
In some studies, the rate of post-transplant fracture is decreasing, in part due to increased 
recognition of the problem, which has resulted in changes in immunosuppressive regimens 
(reduction in dose and duration of glucocorticoids) and earlier identification and treatment 
for osteoporosis (Shane et al., 2004; Compston et al., 2003) 
3.1 Kidney transplantation 
Rates of bone loss are greatest in the first 3-18 months and range from 4-9% at the spine and 
5-8% at the hip. 
After renal transplantation fractures affect appendicular sites (hips, long bones, ankles, feet) 
more commonly than axial sites (spine and ribs). The majority of fractures occur within the 
first 3 years. Fracture prevalence varies from 7-11% in nondiabetic renal transplant 
recipients, but is considerably higher in patient transplanted because of diabetic 
nephropathy and in those who receive kidney-pancreas transplants. (Nowacka-Cieciura et 
al., 2006) 
With regard to the difference in the prevalence of fracture in end stage renal disease patients 
referred to kidney transplant or those who continued dialysis, a large study realized with 
101,039 patients with end stage renal disease demonstrated that kidney transplantation was 
associated with a 34% greater risk of hip fracture than continued dialysis (Nisbeth et al., 
1994). 
3.2 Lung transplantation 
During the first year after lung transplantation, rates of bone loss at the lumbar spine and 
femoral neck range from 2 to 5%. In another study conducted with 70 patients awaiting lung 
transplantation the prevalence of vertebral fractures was 29% in patients with chronic 
obstructive pulmonary disease and 25% in patients with cystic fibrosis (Shane et al., 1996). 
Fracture rates are also high during the first year after lung transplantation, ranging from 18 
to 37%. 
3.3 Cardiac transplantation 
The most rapid rate of bone loss occurs in the first year.  Spinal BMD declines by 6-10% 
during the first 6 months, whereas femoral neck BMD falls by 6-11% in the first year. The 
rate of bone loss slows after the first year and spine BMD may increase after the third year 
(Cohen et al., 2003). Densitometric osteoporosis at the lumbar spine and femoral neck has 
been reported in approximately 28% and 20% respectively of long term transplant patients 
(Chou et al., 2006). 
Vertebral fracture incidence ranges from 20-36% during the first 1 to 3 years after cardiac 
transplantation. One prospective study shows that 36 percent of all patients and 54 percent 
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of women sustained a fracture after this procedure, 85 percent of which occurred within the 
first six months (Shane et al., 1996). Women with the lowest pretransplant hip BMD were at 
highest risk of fracture. In men, pretransplant BMD did not differ between those who went 
on to fracture and those who did not. 
3.4 Liver transplantation 
Spine BMD declines by 2-24% during the first year in earlier studies, particularly during the 
first 3-6 months. Some authors report higher rates of bone loss and fracture in patients who 
have alcoholic cirrhosis, primary biliary cirrhosis, and primary sclerosing cholangitis (Lopez 
1992). Rates of bone loss have been lower in more recent studies. In the second year after 
transplantation, lumbar BMD recovered or even exceeded baseline levels (Guichelaar et al., 
2006). Although early studies showed a predominance of post-transplant bone loss and 
fractures in the lumbar spine (Compston et al., 2003), more recent studies reported higher 
bone loss at the hip (Keogh et al., 1999; Ninkovic et al.,  2002; Crawford et al.,  2006). It seems 
that there are differences in the natural evolution of lumbar and femoral BMD, with greater 
loss of femoral bone that persists after the first year after transplantation. As an example, 
after 3 years, BMD at the femoral neck improved, but still remained below baseline levels 
(Monegal A, 2001). Other studies found a decrease in BMD at the femoral neck at 6 and 12 
months, even despite treatment with bisphosphonates, suggesting a lesser effect of these 
drugs at cortical bone (Keogh et al., 1999), (Ninkovic et al., 2002), (Monegal et al., 2009).  
Fracture rates after liver transplantation are highest in the first 6-12 months. Range from 24 
to 65% and the ribs and spine are the most common sites. Women with primary biliary 
cirrhosis and the most severe preexisting bone disease appear to be at greatest risk. In a 
study of 37 patients receiving liver transplantation between 1993 and 1995, an incidence of 
27% of vertebral fractures in the first three months after transplantation was found 
(Ninkovic et al., 2000). A subsequent study of the same group, done between 1995 and 1998, 
showed that this incidence was only 5%. Between both studies there was a considerable 
reduction in the dose and duration of glucocorticoid treatment, although the use of 
cyclosporine and tacrolimus barely changed (Ninkovic et al., 2002). 
3.5 Bone marrow transplantation  
The pattern of bone loss after bone marrow transplantation (BMT) is different from other 
forms of osteoporosis, being more persistent and severe in cortical bones, such as femoral 
neck than in trabecular bones, such as lumbar spine (Hatutman et al., 2011)). Bone marrow 
transplant (BMT) recipients have many known risk factors for developing decreased bone 
mineral density after transplantation. The pathogenesis of bone disease following BMT 
differs from others form of post-transplantation osteoporosis; recipients are usually younger 
and the time from the diagnosis to the BMT does not exceed 2 years; history of prolonged 
bed rest is uncommon. Immunosuppressive drugs are used in relatively low doses and for 
short periods of time (Ebeling et al., 1999). Glucocorticoid use is restricted to the treatment 
of graft-versus- host disease (GVHD).  
Lumbar spine BMD declines by 2-9% and femoral neck BMD falls 6-11% during the first 
year following transplantation. Lumbar spine BMD begins to recover after 12 months, 
returning to baseline levels at 48 months. The extent of recovery at the femoral neck is less 
(Schulte et al., 2004). The presence of chronic GVHD is another factor associated with higher 
risk of osteoporosis in these patients. Avascular necrosis develops in 10-20% of allogenic 
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BMT patients; its development may be facilitated by a deficit in bone marrow stromal stem 
cell regeneration and low osteoblast number. 
4. PTH. 25-OH-D. Bone remodeling in postransplantation bone disease 
4.1 PTH 
Elevated PTH levels have an adverse effect on bone health increasing turnover and 
decreasing bone mass, especially in cortical bone.  
Some studies reflect a slight increase in PTH levels in the first month after transplantation. It 
could be related to vitamin D deficiency, calcium malabsorption or decreased tubular 
reabsorption of calcium, consequence of steroid treatment (Compston et al., 1996). PTH 
levels may remain elevated in the long-term due to chronic renal failure induced by 
cyclosporin (Floreani A, 2001; Crosbie et al., 1999). 
4.2 25-OH vitamin D  
Inadequate levels of vitamin D have been described in patients with end-stage liver diseases 
prior to liver transplantation, and this may play a role in the aetiology of lower 
mineralization after transplantation. Our group found that 91% of liver transplanted 
patients had insufficient serum levels of 25(OH)D at transplantation time. After adequate 
supplementation, serum 25(OH)D levels increased from 3 months onwards (Guadalix et al., 
2011). A positive correlation between serum 25(OH)D levels at 3 months and BMD increase 
at 6 months was found suggesting that this vitamin has a positive effect on mineralization 
(Crosbie et al., 1999). In our study serum 25(OH)D levels showed positive correlation with 
the percentage change in total hip and femoral neck BMD at 12 months of treatment 
(Guadalix et al.,  2011). These results suggest that vitamin D could have a main role in bone 
loss prevention after liver transplantation. 
4.3 Bone remodeling in postransplantation bone disease  
Bone turnover markers can provide information about the mechanisms of bone loss in post-
transplant period.Our group has previously reported an increase in bone turnover markers 
such as osteocalcin after liver transplantation (Valero et al., 1995; Hawkins et al., 1994). No 
significant changes in urinary hydroxyproline, one and two years after transplant were found; 
however urinary excretion of NTX ( amino-terminal telopeptide of collagen type I) showed a 
significant decrease after two years compared with baseline values(Giannini et al., 2000), while 
other found that values of deoxypyridinoline doubled compared to baseline, two months after 
transplantation (Crosbie et al., 1999). We also found that β-CTX decreased as from 3 months 
both in patients on bisphosphonate treatment as in patients receiving only calcium plus 
vitamin D, reflecting a reduction of bone resorption after liver transplantation (Guadalix et al., 
2011). Greater reductions in β-CTX may be obtained with intravenuous bisphosphonates. A 
significant decrease in urinary deoxypyridinoline in heart transplant recipienters after 
intravenous pamidronate traeatment (Shane et al.,  1998) and in β-CTX levels 6 months after 
liver transplanted in 13 patients treated with intravenous zoledrónico acid (Misof et al., 2008) 
was found. Other investigators found an early increase (one and 3 months after heart 
transplantation) in resorption markers hydroxyproline, pyridonoline and desoxypyridinoline 
and a decreased in osteocalcin, recovering all baseline values at 6 months (Shane et al., 1997). 
Several studies have investigated the OPG / RANKL in the post-transplant period. Results are 
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not homogeneous. High levels of both, OPG and RANKL in the first 14 days after liver 
transplantation compared to the control group were found (Fabrega et al., 2006). In the other 
hand, serum OPG in 57 patients at 3 and 6 months after cardiac transplantation wa correlated 
with bone loss at the lumbar spine and femoral neck sites, after 6 months. Serum OPG alone 
accounted for 67% of the variance of lumbar spine bone density changes over the first 6 
months post transplantation leading to the conclussion that serum OPG levels decline 
consistently in all patients following initiation of immunosuppressive therapy and are 
independently correlated with changes in bone density (Fahrleitner et al., 2003).In another 
study in patients with kidney transplant, levels of OPG and RANKL did not differ between 
healthy volunteers and transplant patients  (Malyszko et al., 2003). 
5. Gonadal status and postransplatation bone disease  
Hypogonadotropic hypogonadism is frequently found both before and after transplantation 
and may play a role in the multifactorial pathogenesis of immunosuppression-induced bone 
loss. Sex-steroid deficiency in either sex results in an increase in bone turnover with an 
imbalance in bone formation and bone resorption. Few studies have assessed the status of 
gonadal function after transplantation and its relationship with bone mass. Many 
premenopausal women and men undergoing solid organ transplantation have temporary 
hypogonadism, most often related to the effects of glucocorticoids and chronic illnesses 
(Fleischer et al., 2008; Tauchmanovà et al., 2005). In some cases (i.e. chemotherapy and/or 
radiation therapy for hematopoietic stem cell transplantation), hypogonadism is permanent 
(Tauchmanovà et al., 2003). In men and women undergoing transplantation, testosterone 
and estrogen-progestin replacement, respectively, have been shown to slow bone loss 
(Isoniemi et al., 2001; Kananen et al., 2005). Hypogonadism is a common finding among 
patients with terminal liver disease, especially in males. Incidence was estimated up to 70% 
(Guichelaar et al., 2004). There are few studies about change in sex hormones after liver 
transplantation, some authors have reported an increase in free testosterone, although the 
recovery of normal levels has not been achieved in all patients (Floreani et al., 2001; Monegal 
et al., 2001). In a study of 10 liver transplant recipients followed for 12 months after 
transplantation, before transplantation, 90% of patients had a decrease in testosterone levels 
and reported decreased libido and erectile dysfunction .After transplant, total testosterone 
levels had doubled, and free testosterone increased tenfold. Patients reported early 
improvement in sexual function (6 to 8 weeks after transplantation). It was suggested that 
pretransplant abnormalities in gonadal function are mainly due to liver failure and are 
reversible in most patients (Madersbacher  et al., 1996). In premenopausal women, normal 
menses usually resumes after liver transplantation (Mass et al., 1996). 
Low levels of testosterone are quite common early after cardiac transplantation, and may be 
found in up to 50% of men (Guo et al., 1998). In addition, a significant relationship between 
low levels of serum testosterone and rates of femoral neck bone loss during the first 6 month 
after transplantation have been found by some authors (Shane et al., 1997). Fleischer et al., 
(2008) studied 108 male heart transplant patients. One month after transplantation, total 
testosterone levels were below normal in 63% of them while 33% had decreased levels of 
free testosterone. 15% of patients had elevated gonadotropin a month after transplantation, 
increasing to 29% at 6 months. These data suggest a suppression of the hypothalamic-
pituitary-gonadal axis immediately after transplantation, with subsequent recovery. 
Authors attributed this to steroid therapy. Prednisone dose was found to be the main 
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determinant of the values of total and free testosterone). No relationship was found between 
post-transplant bone loss and testosterone levels, probably because patients were treated 
with calcitriol or alendronate. 
In most studies, testosterone levels return to normal by 6 to 12 months after transplantation 
(Sambrook et al.,  1994) but up to 20% of patients receiving prednisone and cyclosporine A 
may persist with low serum total testosterone levels 3 years after cardiac transplantation 
(Stempfle et al.,  1999). 
Regarding the role of other immunosuppressive agents on gonadal function cyclosporine A 
decreases testosterone by affecting both the hypothalamic-pituitary- gonadal axis (Sikka et 
al., 1988) and by direct inhibition of testicular synthesis of testosterone in murine models 
(Seethalakshmi et al., 1990). However, cyclosporine did not seem to affect testosterone levels 
in humans (Fleisher et al., 2008; Samojlik et al., 1992). 
Some authors recommend hormonal treatment in post transplant osteoporosis in men and 
premenopausal women with hypogonadism, if there are no contraindications (Shane et al., 
2009 up-to-date). Androgen replacement therapy has shown skeletal benefit (increase in 
BMD) only in men with hypogonadism. It has been demonstrated in an uncontrolled study 
of postmenopausal liver transplantation recipients, that the use of transdermal estradiol was 
effective in increasing BMD of lumbar spine and femoral neck over a period of two years 
(Isoniemi et al., 2001).  
6. Prevention and treatment of osteoporosis  
6.1 General measures before transplantation  
The same measures used to prevent osteoporosis in the general population apply to 
transplant recipients, regardless of the pretransplant BMD measurement. It is recomended 
that all candidates for organ transplantation follow a throughfully evaluation in order to 
identificate and correct risk factors and to implement measures to improve bone health 
(Table 4).  
 
Before Transplantation After transplantation 
- Measurement lumbar spine and hip 
BMD. If BMD is low, it should be 
evaluated secondary causes of 
osteoporosis. 
- Patients with kidney failure should be 
avaluated and treated for renal 
osteodystrophy. 
- Perform spine radiograph to detect 
prevalent fractures. 
- Recommend appropriate intake of 
calcium (1000-mg/day) and vitamin D 
(800 IU). 
- Patients with osteoporosis should be 
evaluated and treated according to 
general guidelines. 
- Consider initiating preventive therapy 
in most patient (even those with 
normal BMD): calcium, vitamin D and 
antiresorptive agents. 
 
- Perform annual BMD measurement. 
 
- Perform annual Spine Radiograph. 
 
- Annual measurement of bone 
turnover markers. 
Table 4. General recommendations for prevention and treatment of osteoporosis 
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Lifestyle factors, such as immobilization, smoking, and alcohol abuse, should be avoided. 
Concomitant use of medications that can negatively impact skeletal health should be 
minimized whenever possible. Hypogonadism should be sought and corrected, particularly 
in males, where symptoms are easily confounded with those of preexisting chronic disease 
or adverse effects of concomitant medication. All patients should receive the recommended 
daily allowance for calcium (1000-15000 mg/day) and vitamin D (800 IU/day). Higher 
vitamin D doses should be given if the patient is vitamin D deficient (serum 25-
hydroxyvitamin D level >20 ng/ml [50 nmol/L]). Although calcium and vitamin D do not 
prevent transplantation-related bone loss, randomized trials assessing antiresorptive 
therapy, such as bisphosphonates, have been carried out in the setting of concomitant 
calcium and vitamin D repletion.  
Prevention of early bone loss after transplantion have been reported with specific resistance 
training programs (Mitchell et al., 2003). Regular weight-bearing exercise (30 minutes, three 
times per week) has proved also to be beneficial for the prevention and treatment of 
osteoporosis. Because of the high prevalence of osteopenia and osteoporosis in patients 
awaiting transplantation and the morbidity caused by osteoporosis after transplantation, it 
is recommended that candidates for organ transplantation undergo measurements of BMD 
of the hip and spine, preferably at the time of acceptance to the waiting list. Low BMD 
before transplantation has been pointed out as a risk factor for fractures after 
transplantation. In addition, spine radiographs should be performed to detect prevalent 
fractures .Patients who have a history of fracture or have osteoporosis on DXA (T-score ≤ -
2.5) before transplantation should be evaluated for secondary causes. When a secondary 
cause (i.e. hypogonadism) is identified, appropriate treatment is recommended prior to 
transplant. In addition to the treatment (when possible) of secondary causes, some patients 
may benefit from additional osteoporosis therapy, such as bisphosphonates, while awaiting 
transplant. Patients with osteopenia should be considered for prevention (calcium, vitamin 
D and/or antirresorptives) evaluating  risk factors. Alternatively, patients with normal BMD 
can defer medical therapy until immediately after transplantation. For patients with end-
stage renal disease, an evaluation and treatment for renal osteodystrophy according to 
accepted guidelines is highly recommended.  
6.2 Therapeutic measures of post-transplantion bone loss  
Several drugs have been studied for the treatment of osteoporosis after transplantation. Many 
of these studies were done with small number of patients, were not randomized or not 
compared with control group. Also, patients were not selected based on T-score or risk factor 
(beyond the transplant). There is no consensus on candidates for the treatment or the drug of 
choice.Given the accelerated bone loss that occurs immediately after transplantation many 
experts recommend preventive treatment for all patients receiving solid organ transplantation, 
regardless of pretransplant BMD (Maalouf NM, 2005; Cohen et al.,   2006). This approach is 
based on observational data that show an overlap in BMD values between the pre-transplant 
patients with posttransplant fracture and those without fractures (Leidig-Bruckner et al.,   
2001; Shane et al., 1996). The lack of reliable clinical predictors to identify individual patients 
who will experience osteoporotic fractures renders all transplant recipients candidates for 
preventive therapy. Treatment should be started immediately after transplantation.  
Since lumbar BMD starts to recover in many patients at 12 months after transplantation, 
long-term treatment may be unnecessary (Cohen et al., 2006). Duration of treatment 
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depends on patient characteristics, such as time of steroid therapy withdrawal, presence of 
other risk factors for low bone mineral density and fractures as well as information 
provided by the measurement of BMD. 
Another approach to the management of transplanted patients is to apply similar guidelines 
as those used for the prevention of glucocorticoid-induced osteoporosis. There are several 
guidelines for the prevention of glucocorticoid-induced osteoporosis. Collectively, they 
suggest preventive therapy for patients with clinical risk factors for osteoporosis and 
fracture (age ≥65 years, previous fragility fracture) or in patients without other risk factors if 
BMD T-score is below -1.0 or -1.5 (Shane E, 2009). 
6.2.1 Bisphosphonates  
These potent antiresorptive agents are an obvious option in preventing the rapid bone loss, 
that occurs mainly in the early phase after transplantation. Bisphosphonates are considered 
the medical therapy of choice for the prevention of transplantation-related bone loss. 
Although there are conflicting data both oral and intravenous bisphosphonates appear to be 
effective in these patients. 
Below shows some of the results obtained with bisphosphonates treatment in different types 
of transplants.  
In a study of 99 subjects receiving stem cell transplantation, patients were randomly 
assigned to receive calcium and vitamin D or calcium and vitamin D plus pamidronate (60 
mg intravenously six times over the first post-transplant year). Treatment with pamidronate 
prevented spine bone loss (0 percent in pamidronate group versus -2.9 percent in calcium 
group), and reduce hip bone loss (-5.5 percent and -7.8 percent in the pamidronate and 
calcium-vitamin D groups, respectively) (Kananen et al.,   2005). 
In a trial of 62 adults undergoing liver transplantation, patients were randomly assigned to 
receive infusions of zoledronic acid (4 mg) or placebo within seven days of transplantation. 
BMD was measured 3, 6, 9, and 12 months later. Zoledronic acid group lost significantly less 
bone at the hip at all time points (Crawford BA, 2006). In the spine, the zoledronic acid 
group lost less bone at three months, but the difference between the two groups was no 
longer significant at 12 months because of improvements between 3 and 12 months in the 
placebo group. Zoledronic acid sometimes caused postinfusion hypocalcemia and 
temporary secondary hyperparathyroidism. 
Oral bisphosphonates are also effective in preventing bone loss after transplantation (Shane et 
al., 2004; Atamaz et al., 2006). As an example, in a trial of 98 subjects receiving a liver 
transplant, subjects randomly assigned to alendronate (70 mg weekly) versus no alendronate 
had significant increases in lumbar spine (5.1and 8.9 percent) and femoral neck (4.3 and 8.7 
percent) BMD at 12 and 24 months, respectively, compared with the control group (Atamaz et 
al.,  2006). All subjects received calcium (1000 mg daily) and calcitriol (0.5 mcg daily). 
Our group studied the effect of risedronate in liver transplant patient. The main findings 
of our study are that liver transplanted patients with low bone mineral density who 
receive either Risendronate combined with calcium and vitamin D3 or vitamin D3 and 
calcium alone showed a significant increase in spine BMD at 12 months compared to 
baseline values. In addition, risedronate patients showed a significant increase in 
intertrochanteric BMD, but we were not able to find any significant differences between 
groups. Hence, these results suggest that weekly risedronate after liver transplantation 
combined with 1000 mg/day of calcium and 800 IU/day of vitamin D are not superior to 
the administration of calcium and vitamin D alone (Guadalix S, 2011). Significant 
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improvement in BMD at the lumbar spine was also observed 12 months after liver 
transploant in the control group. This response may be related to the administration of 
calcium and vitamin D3 itself, but also to improvement in general health, mobility, muscle 
mass, and nutrition as a consequence of better liver function. 
A recent meta-analysis in 364 liver transplant patients from 6 randomized controlled trials 
have found that bisphosphonate therapy improved lumbar spine BMD by 0.03 g/cm2 (95% 
CI 0.01-0.05 g/cm2, p=0.02) at 12 months post-liver transplantation compared to the control 
group. However, a statistically significant change in femoral neck BMD could not be 
demonstrated in this meta-analysis. Data on fractures could not be analyzed (Kasturi et al., 
2010). In a study of 34 lung transplant recipients (with cystic fibrosis antecedents), 
pamidronate therapy versus calcium and vitamin D showed a significant increase in bone 
mass at 2 years in lumbar spine and total femur. There was no difference in fracture 
incidence (Aris et al.,   2000). 
In patients after allogenic stem cell transplantation pamidronate reduced bone loss at the 
spine, femoral neck and hip by 5.6, 7.7 and 4.9% respectively after 12 month of treatment. 
However, at 24 month, only differences at BMD of total hip remained statistically significant 
between study groups (Grigg et al., 2006). Other study in 12 patients treated with zoledronic 
acid show that 12 month after infusion, total hip BMD increased in 75% of the patients and 
femoral neck BMD increased in 11 of 12 patients. Spinal BMD only increase in four (D’Souza 
et al., 2006). 
Based upon the above trials, we suggest bisphosphonates as first choice for prevention of 
transplantation-related bone loss. There are few data to support the use of one 
bisphosphonate over another. Many of the trials used intravenous bisphosphonates due to 
ease of administration, especially in post-transplant patients who are required to take many 
oral medications. There are no trials comparing oral to intravenous bisphosphonates in the 
immediate post-transplant setting. The decision should be based upon individual patient 
preferences and abilities. The safety and efficacy of bisphosphonates for prevention of 
transplantation-related bone loss in patients with chronic kidney disease has not been 
carefully evaluated, and in general, there is limited data on the level of renal impairment at 
which bisphosphonate use should be avoided and whether this level is the same for iv 
bisphosphonates. In the majority of trials, individuals with serum creatinine concentrations 
above the upper limits of normal were excluded from participation. Despite these concerns, 
however, it is usually recommend their use after renal transplantation, at least during the 
first year when rates of bone loss are most rapid.  
6.3 Other therapies 
Replacement doses of calcium and vitamin D (400-1000 IU/day) do not prevent clinically 
significant bone loss after transplantation, but active metabolites of vitamin D could reduce 
post-transplantation bone loss, probably by reversing glucocorticoid-induced decreases in 
intestinal calcium absorption. 
6.3.1 Calcidiol (25-hydroxivitamin D) and alfacalcidol (1-hydroxivitamin D)  
In renal transplant recipients calcidiol (40 µgr/day) prevents spine and femoral bone loss 
and is associated with a significant decrease in vertebral deformities (Talalaj et al.,   1996). 
Consistently with these findings, our group have found that in patients randomized 
immediately after cardiac transplantation to  32000 IU/week of oral calcidiol for 18 months, 
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lumbar spine BMD increased 5%, whereas those who received cyclical etidronate or nasal 
calcitonin, showed decreases in spine BMD (Garcia-Delgado et al.,   1997). Also, alfacalcidol 
therapy has been associated with an increase in BMD or prevention of additional bone loss 
in renal (El-Agroudy et al.,   2003) and cardiac recipients ( Van Cleemput et al.,   1996). 
6.3.2 Calcitriol  
Calcitriol may suppress bone resorption indirectly by facilitating intestinal calcium 
absorption and suppressing PTH secretion. Studies of calcitriol alone and those that 
compare calcitriol and bisphosphonates suggest that calcitriol may also prevent early post-
transplant bone loss, particularly at the proximal femur. Positive effects on BMD have been 
found with higher doses of calcitriol (> 0.50 µgr/day) in heart, lung or renal transplantation, 
whereas lower doses (0.25 µgr/day) are relatively ineffective. Use of calcitriol requires close 
monitoring of serum and 24 hour urine calcium, because it is associated with hypercalcemia 
and hypercalciuria in >50% patients.In a study of 65 patients undergoing cardiac or single 
lung transplantation, patients were randomly allocated to receive placebo or calcitriol (0.5-
0.75 microg/day), the latter for either 12 months or 24 months. Bone loss at the proximal 
femur was significantly reduced or prevented by treatment with calcitriol for 2 years 
compared with treatment with calcium alone (Sambrook et al.,   2000).  
Other randomized study compared the efficacy of 6 months treatment with either calcitriol 
(0.5 microg/day) or two cycles of etidronate plus calcium in preventing bone loss in 41 
patients undergoing cardiac or lung transplantation. Compared with an untreated reference 
group, both therapies offered significant protection at 6 months in lumbar spine and 
etidronate provided significant protective carryover after therapy had been discontinued 
(Henderson et al.,  2001).Although calcitriol appears to be effective in preventing bone loss 
after transplantation (Sambrook et al.,   2000; Shane E, 2004) it should not be selected as first-
line treatment because of their limited effectiveness and narrow therapeutic window.  
6.3.3 Calcitonin 
Although calcitonin is effective in preventing bone loss in postmenopausal women, it has 
not been shown to be superior to calcium in transplant recipients (Välimäki et al., 1999). In 
one trial, the combination of continuos oral calcitriol (0.5 microg/day) and nasal salmon 
calcitonin (200 U/day) for the first 3 months was inferior to intravenous pamidronate (0.5 
mg/kg body weight) every third month in attenuating bone loss three months after cardiac 
transplant but similar at 18 months in 26 cardiac transplant recipients (Bianda et al., 2000). 
6.3.4 Recombinant parathyroid hormone (PTH)  
PTH 1-34 (teriparatide) has been shown to improve BMD in patients with glucocorticoid-
induced osteoporosis, but there are few studies evaluating PTH for the prevention of post-
transplant osteoporosis. It a small trial 24 kidney recipients patients were treated with 20 µg 
of teriparatide/daily/6 months, it was shown that femoral neck BMD was stable compared 
to the placebo group. Lumbar spine BDM and radial BMD, histomorphometric bone volume 
and bone matrix mineralization status remained unchanged in both groups. (Cejka et al.,  
2008). Recombinant parathyroid hormone (PTH) has not been well studied in this 
population. Patients who have received total body irradiation during hematopoietic stem 
cell transplantation or who have primary or secondary elevations in PTH are not candidates 
for recombinant PTH therapy. 
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6.3.5 New therapies  
Promising new agents for transplantation osteoporosis include new potent anticatabolic 
drugs such as human antibodies to receptor activator of nuclear factor kb-ligand (RANKL) 
(denosumab), and catepsin k inhibitors. 
6.4 Monitoring  
There is no consensus on the optimal strategy for monitoring patients on therapy. Patients 
on antiresorptive therapy are measured BMD every year after transplantation. Patients with 
normal BMD can be follow up with DXA every two years, depending also of other risk 
factors . In patients who require continuous treatment with glucocorticoids (prednisone ≥ 5 
mg / day), BMD measurement is recommended annually. An effort should be made to find 
the lowest prednisone dose compatible with graft survival.  
7. Summary and conclusions  
Although bone loss and fractures after transplantation seem to be lower than those reported 
years ago, they remain being a main long term postransplant complication. An effective 
approach should incorporate pre-transplant measures to detect and to treat preexisting bone 
diseases. Oral or intravenous bisphosphonates, in conjunction with calcium and vitamin D, 
are effective in preventing post-transplantation bone loss when started shortly after grafting. 
The optimal dose, timing, and frequency, particularly of intravenous bisphosphonate 
administration, remain to be determined. At present, most controlled trials lack sufficient 
statistical power to demonstrate efficacy for fracture prevention, so treatment regimens are 
based on results of effects on the surrogate end-points, bone densitometry, and bone 
turnover markers. More studies are required to determine the best agent and route of 
administration to prevent this common complication of organ transplantation. The future 
challenge is to achieve adequate immunosuppression without corticosteroids, with drugs 
not damaging bone. This approach, together with improved bone health before the 
transplant would be an effective strategy to reduce post-transplant osteoporosis. 
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